Prevalence of non-motor symptoms in Parkinson’s disease using the Movement Disorder Society-Non-Motor Rating Scale (MDS-NMS) and comparable scales
Objective: To analyze the frequency and differences in distribution by sex and disease severity of non-motor symptoms (NMS) in patients with Parkinson’s disease (PD) using…Sexual dysfunction precedes the classical motor symptoms of Parkinson’s disease?
Objective: To investigate whether sexual dysfunction precedes the classical motor symptoms of Parkinson’s disease. Background: There is growing evidence that some symptoms can precede the…A Parkinson’s disease (PD) case with underlying cerebral small vessel disease (CSVD)
Objective: Emphasis of CSVD in PD through clinical-pathological correlation study. Background: PD affects 1.7%, while CSVD affects about 45% [1], of the population aged over…Parkinson’s disease and osteocalcin pilot study: Is there a protective role of bone in neurodegeneration?
Objective: To characterize the relationship between the bone-derived hormone osteocalcin (OCN) and Parkinson’s disease (PD) in humans, and explore sex and treatment differences. Background: The…Neuroimaging of anxiety in Parkinson’s disease: a systematic review
Objective: The aim of this systematic review was 1) to identify the brain regions involved in anxiety in Parkinson's disease (PD) based on neuroimaging studies,…Clinical and neurological features of the course of parkinsonism in the presence of chronic renal disease
Objective: To study the clinical and neurological features of the course of parkinsonism in chronic renal disease. Background: Under our supervision were 30 patients with…IncobotulinumtoxinA to treat sialorrhea in Parkinson’s disease: A real-life study
Objective: We evaluate the long-term efficacy and safety of incobotulinumtoxinA injections in advanced Parkinson’s disease (PD) patients suffering from sialorrhea (10 injection cycles into the…Assessing the Safety and Tolerability of ABBV-951 (Foscarbidopa/Foslevodopa) in Advanced Parkinson’s Disease Patients During a 52-Week Phase 3 Study: Study Design and Updated Patient Baseline Characteristics
Objective: To evaluate the local and systemic safety and tolerability of ABBV-951 (foscarbidopa/foslevodopa) delivered 24 h/day as a continuous subcutaneous infusion (CSCI) for up to…Reduction of OFF time with apomorphine infusion during hours of pump use: Analysis from a Phase III, open-label study
Objective: Evaluate the efficacy of apomorphine (APO) infusion in reducing OFF time during the hours of pump use in PD patients with motor fluctuations inadequately…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.